Navigation Links
Smith & Nephew Introduces New Biologic to Speed Healing
Date:3/5/2008

New Biologic uses patient's own blood to assist in healing

MEMPHIS, Tenn. and SAN FRANCISCO, March 5 /PRNewswire-FirstCall/ -- Smith & Nephew, Inc.'s (NYSE: SNN, LSE: SN) Orthopaedic Trauma & Clinical Therapies business today announced the U.S. launch of the CAPTION(TM) Disposable Platelet Concentration System. The CAPTION system simplifies and expedites the collection of platelet rich concentrate (PRC) and eliminates cross- contamination risks.

The CAPTION system is used by the surgical staff to concentrate the platelets from a sample of the patient's blood. Platelets are round cell fragments in the blood that are responsible for initiation of the body's natural healing process. When the concentrated platelets are applied to the surgical site, they may help jump start the body's natural healing response.

The CAPTION system creates a PRC of up to four times the original level and takes 40% less time than standard centrifugation. Furthermore, the disposable CAPTION system arrives sterile and all materials are disposed after use, eliminating the risk of cross-contamination. The PRC made by the CAPTION system consists of platelet cells suspended in a proprietary solution.

"Until now the preparation of platelet rich concentrate has been burdensome for my surgical staff," says Dr. Steven Moran from the Mayo Clinic in Rochester, MN. "Fortunately, the new CAPTION system allows for the simple and rapid collection of platelet rich concentrate, without the hassle of a centrifuge."

The CAPTION system was developed by Smith & Nephew scientists and innovation teams based at the company's Research Center in York, UK, and at the Orthopaedic Trauma & Clinical Therapies Global Business Unit in Memphis, Tenn.

"We are proud to be able to offer this new technology to our customers. The product application is universal because platelets naturally aid in the healing process of multiple tissue types," said Mark Augusti, president of Smith & Nephew Orthopaedic Trauma & Clinical Therapies. "CAPTION is also a great example of what great things two cutting-edge teams can accomplish for the good of our customers and their patients."

The CAPTION system joins the company's biologic portfolio, which includes the EXOGEN 4000+(TM) ultrasound bone healing system and SUPARTZ(R) treatment the world's number one joint fluid therapy for pain reduction of the knee.

(TM) Trademark of Smith & Nephew.

SUPARTZ is a registered trademark of the Seikagaku Corporation.

About us

Smith & Nephew is a global medical technology business, specializing in Orthopaedic Trauma & Clinical Therapies, Orthopaedic Reconstruction, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2007 were nearly $3.4 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward- looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.


'/>"/>
SOURCE Smith & Nephew, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Smith & Nephew Announces Breakthrough VERILAST(TM) Technology
2. Robert H. Smith Feeding the Future with $15 Million Gift to Hebrew University of Jerusalem
3. Smith & Nephew Wins OXINIUM(TM) Approval in Japan
4. Smith & Nephew Orthopaedic Reconstruction Global Management Team Announced
5. Celebrity Cook Paula Deen and Husband Michael Groover Bring Smithfield Foods Helping Hungry Homes(TM) Tour To Feed New Orleans Families
6. EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
7. Celebrity Cook Paula Deen and Husband Michael Groover Bring Smithfield Foods Helping Hungry Homes(TM) Tour to L.A.
8. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
9. Senator Sam Brownback and Rep. Chris Smith to Speak at Blogs for Life
10. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Security Capital Assurance Ltd.
11. AUDIO from Medialink and GlaxoSmithKline: Get Ready to Get Moving to a New You in the New Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: